Corcept Therapeutics Analyst Ratings
Corcept Therapeutics (CORT) Receives a Buy From Piper Sandler
Corcept Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Corcept Therapeutics, Maintains $65 Price Target
Corcept Therapeutics Analyst Ratings
Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating
Truist Financial Sticks to Its Buy Rating for Corcept Therapeutics (CORT)
Corcept Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
HC Wainwright & Co. : Corcept Therapeutics (CORT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $38.00.
Corcept Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Corcept Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)
Analysts' Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Corcept Therapeutics: Hold Rating Amidst Generic Competition and Legal Challenges
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)